论文部分内容阅读
目的 探讨原发性肝癌（ＰＬＣ）患者血清磷脂酶Ａ_２活性的变化及临床意义。方法 采用［~３Ｈ－油酸标记生物膜法检测了６０例 ＰＬＣ患者（其中 Ｉ、Ⅱ、Ⅲ期肝癌患者分别为 １４例、２３例、２３例）以及１６ 例手术切除肿瘤后和 １９例肝动脉栓塞化疗后患者血清ＰＬＡ_２的动态变化。结果 ＰＬＣ患者血清ＰＬＡ_２活性 ２９．２７± ４． １５（％）明显高于对照组 ８．４２± ２．０１（％）；且不同临床分期肝癌患者之间ＰＬＡ_２活性相差显著（ Ｐ＜ ０． ０５），随患者病情加重，ＰＬＡ_２活性呈递增趋势；ＰＬＡ_２活性≥３０． ０（％）和＜ ３０． ０（％）者一年生存率分别为 ３２．０％和 ７５． ０％；手术切除肿瘤后和化疗有效者ＰＬＡ_２活性较治疗前均有明显降低（ Ｐ＜ ０． ０５）。结论 ＰＬＡ_２可作为ＰＬＣ辅助诊断及估计病情的血清学指标之一，对了解 ＰＬＣ 患者体内肿瘤体积大小、病程发展、疗效评价及预后估计有一定的作用。
Objective To investigate the changes of serum phospholipase A 2 activity in patients with primary liver cancer (PLC) and its clinical significance. Methods Sixty cases of PLC patients (14 cases of I, II, and III liver cancer, 23 cases of 23 cases) and 16 cases of surgical resection of the tumor and 19 cases of liver Dynamic changes of serum PLA_2 in patients after arterial chemoembolization. Results PLA2 activity in PLC patients was 29.27 ± 4. (%) Was significantly higher than that of the control group (8.42 ± 2.01%). The activity of PLA 2 in patients with different clinical stages of hepatocellular carcinoma was significantly different (P 0. 05). The PLA 2 activity increased with the progression of the patients ; PLA_2 activity ≥30. 0 (%) and <30. 0 (%) one-year survival rates were 32.0% and 75. 0%. The activity of PLA 2 after surgery and chemotherapy was significantly lower than that before treatment (P <0.05). Conclusions PLA_2 can be used as one of the serological markers for PLC-assisted diagnosis and prognosis evaluation. PLA2 has some effects on the size of tumor, progression of disease course, curative effect evaluation and prognosis estimation in PLC patients.